Natriuretic Peptides (ANP, BNP, CNP)

# Natriuretic Peptides (ANP, BNP, CNP): The Cardiac Hormone Family Governing Cardiovascular, Renal, and Metabolic Research

The natriuretic peptide (NP) system represents one of the most consequential discoveries in cardiovascular biology. Since the landmark 1981 finding by Adolfo de Bold that atrial myocardial extracts produce a rapid natriuretic response in laboratory models (de Bold et al., 1981), the field has expanded into a rich ecosystem of three structurally related peptide hormones — atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) — their cognate receptors, and a signaling cascade centered on the second messenger cyclic guanosine monophosphate (cGMP).

Today, natriuretic peptides are indispensable tools in cardiovascular, renal, metabolic, and skeletal research. BNP and its amino-terminal fragment NT-proBNP serve as the most widely measured biomarkers in cardiac research, while synthetic CNP analogs have opened new frontiers in skeletal biology. This guide provides a comprehensive, research-oriented overview of the natriuretic peptide family for laboratory investigators.

---

Discovery and Historical Context

The Birth of a Field

The heart was long regarded as a purely mechanical pump. That paradigm shifted definitively in 1981, when de Bold and colleagues injected crude atrial myocardial extracts into laboratory rodent models and observed a rapid, potent increase in sodium and water excretion — a natriuretic and diuretic response that implied the heart was also an endocrine organ (de Bold et al., 1981). By 1984, the responsible factor was isolated and sequenced, yielding the 28-amino-acid ring peptide now known as atrial natriuretic peptide (ANP).

The identification of a second cardiac natriuretic peptide followed in 1988, when Sudoh and colleagues isolated a 32-amino-acid peptide from porcine brain tissue, naming it brain natriuretic peptide (BNP). Despite its name, BNP is predominantly synthesized in ventricular cardiomyocytes and is released in response to myocardial wall stress. The third family member, C-type natriuretic peptide (CNP), was identified in 1990 from porcine brain and distinguished itself by its paracrine rather than endocrine mode of action and its preferential expression in endothelial cells and the central nervous system.

Convergent Evolution of Understanding

Together, these discoveries established the concept of a cardiac natriuretic peptide system (NPS) — a counter-regulatory axis that opposes the vasoconstrictive, sodium-retaining effects of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (Nishikimi et al., 2006). This conceptual framework has proven foundational for decades of cardiovascular research.

---

Molecular Biology and Structure

Peptide Structures

All three natriuretic peptides share a conserved 17-amino-acid disulfide ring formed by an intramolecular cysteine bridge, which is essential for receptor binding and biological activity. They differ primarily in their amino- and carboxy-terminal extensions:

•ANP (28 amino acids): Synthesized as a 126-amino-acid prohormone (proANP) stored in atrial granules. Proteolytic cleavage by the transmembrane serine protease corin releases the mature C-terminal 28-residue peptide upon atrial stretch. ANP circulates as a true endocrine hormone.

•BNP (32 amino acids): Produced primarily by ventricular cardiomyocytes from a 108-amino-acid prohormone (proBNP). Cleavage by corin and furin releases the biologically active C-terminal BNP and the inert N-terminal fragment NT-proBNP, both of which enter the circulation. BNP expression is upregulated under conditions of ventricular volume and pressure overload.

•CNP (22 or 53 amino acids): Exists in two bioactive forms, CNP-22 and CNP-53, derived from a 126-amino-acid prohormone. Unlike ANP and BNP, CNP lacks a C-terminal tail extension beyond its ring structure. It functions predominantly as a paracrine and autocrine mediator in the vasculature, skeleton, and central nervous system rather than as a circulating hormone.

Gene Regulation

The three peptides are encoded by separate genes: NPPA (ANP), NPPB (BNP), and NPPC (CNP). Gene expression is regulated by distinct stimuli. NPPA and NPPB are responsive to mechanical stretch, hypoxia, and neurohormonal factors including endothelin-1 and angiotensin II. NPPC expression is driven by shear stress in endothelial cells and by growth factors including fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β) in chondrocytes (Potter et al., 2009).

---

Natriuretic Peptide Receptors

Three Receptor Subtypes

The biological actions of natriuretic peptides are mediated through three distinct receptors, designated NPR-A (also known as GC-A or NPR1), NPR-B (GC-B or NPR2), and NPR-C (NPR3). Understanding receptor pharmacology is essential for interpreting research findings (Potter et al., 2006).

#### NPR-A (Guanylyl Cyclase-A)

NPR-A is the primary signaling receptor for ANP and BNP, with a binding affinity order of ANP ≥ BNP >>> CNP. It is a single-pass transmembrane receptor comprising an extracellular ligand-binding domain, a transmembrane segment, an intracellular kinase-homology domain (KHD), a dimerization domain, and a C-terminal guanylyl cyclase catalytic domain. Upon ligand binding, the receptor's intrinsic guanylyl cyclase activity converts GTP to cGMP, activating downstream effectors including cGMP-dependent protein kinase (PKG), cGMP-gated ion channels, and cGMP-regulated phosphodiesterases (Pandey, 2011).

NPR-A is expressed abundantly in the kidney, adrenal glands, vasculature, heart, lung, adipose tissue, and brain. The receptor's phosphorylation state serves as a critical regulatory mechanism — dephosphorylation of the KHD renders the receptor refractory to ligand-stimulated cGMP production, a process termed homologous desensitization.

#### NPR-B (Guanylyl Cyclase-B)

NPR-B is the primary signaling receptor for CNP, with a binding affinity order of CNP >> ANP ≥ BNP. Its domain architecture mirrors that of NPR-A, including the intracellular guanylyl cyclase domain and cGMP-generating capacity. NPR-B is expressed in the brain, vasculature, bone (particularly the growth plate), fibroblasts, and reproductive tissues (Pandey, 2005).

Loss-of-function mutations in the NPR2 gene (encoding NPR-B) result in acromesomelic dysplasia type Maroteaux in humans, characterized by severe short stature — a finding that established CNP/NPR-B signaling as essential for endochondral bone growth.

#### NPR-C (Clearance Receptor)

NPR-C differs fundamentally from NPR-A and NPR-B in that it lacks an intracellular guanylyl cyclase domain. Historically classified as a "clearance receptor" responsible for binding and internalizing all three natriuretic peptides for lysosomal degradation, NPR-C also possesses signaling capabilities. Its short intracellular tail can couple to inhibitory G proteins (Gαi), modulating adenylyl cyclase activity and phospholipase C signaling. NPR-C binds all three natriuretic peptides with similar affinity.

NPR-C is the most abundantly expressed natriuretic peptide receptor in many tissues. Its clearance function, together with enzymatic degradation by neprilysin (NEP, neutral endopeptidase 24.11), determines the circulating half-lives of natriuretic peptides — approximately 2–3 minutes for ANP, 20 minutes for BNP, and 120 minutes for NT-proBNP (which is cleared renally rather than by NPR-C or neprilysin).

---

Cardiovascular Research Applications

Hemodynamic and Vascular Effects

ANP and BNP exert potent effects on cardiovascular hemodynamics through NPR-A/cGMP signaling:

•Vasodilation: cGMP-PKG signaling in vascular smooth muscle cells reduces intracellular calcium concentration and dephosphorylates myosin light chain, producing relaxation. ANP and BNP reduce both arterial and venous tone, decreasing systemic vascular resistance and venous return.

•Natriuresis and diuresis: In the kidney, ANP increases glomerular filtration rate (GFR) through afferent arteriolar dilation and efferent arteriolar constriction, enhances sodium excretion by inhibiting sodium reabsorption in the inner medullary collecting duct, and suppresses renin secretion from juxtaglomerular cells.

•RAAS inhibition: Natriuretic peptides directly suppress renin release, aldosterone secretion from adrenal glomerulosa cells (via cGMP-dependent inhibition of cAMP), and angiotensin II-mediated effects, positioning the NPS as a direct counter-regulatory system to RAAS (Volpe et al., 2008).

Cardioprotective Research

In vitro and in vivo studies have revealed significant cardioprotective actions of natriuretic peptides that extend beyond their hemodynamic effects:

•Anti-hypertrophic activity: ANP inhibits cardiomyocyte hypertrophy through cGMP/PKG-mediated suppression of the calcineurin-NFAT and MAPK/ERK pathways. Genetic deletion of NPR-A in rodent models produces cardiac hypertrophy and fibrosis independent of blood pressure changes, confirming a direct local cardioprotective role (Nishikimi et al., 2006).

•Anti-fibrotic activity: ANP and BNP suppress cardiac fibroblast proliferation and collagen synthesis. The cGMP/PKG pathway inhibits the pro-fibrotic signaling of TGF-β and endothelin-1, reducing extracellular matrix deposition.

•Anti-inflammatory effects: Natriuretic peptides modulate macrophage polarization and reduce inflammatory cytokine production in experimental models of myocardial injury, suggesting immunomodulatory roles in cardiac tissue remodeling.

CNP in Vascular Biology

While ANP and BNP function as circulating hormones, CNP acts as a local vascular regulator. Produced by endothelial cells, CNP activates NPR-B on underlying vascular smooth muscle cells, producing vasodilation and inhibiting smooth muscle proliferation. CNP research has revealed roles in:

•Maintaining vascular tone and preventing neointima formation after vascular injury
•Regulating endothelial permeability and leukocyte adhesion
•Modulating angiogenesis through effects on endothelial cell migration and tube formation

---

BNP and NT-proBNP as Research Biomarkers

Biochemical Rationale

The differential processing and clearance of BNP-derived fragments has made them invaluable research biomarkers. When proBNP (108 amino acids) is cleaved, it yields equimolar amounts of the biologically active BNP (32 amino acids, C-terminal) and the inert NT-proBNP (76 amino acids, N-terminal). Their markedly different half-lives (BNP ~20 minutes vs. NT-proBNP ~120 minutes) and clearance mechanisms (BNP via NPR-C and neprilysin vs. NT-proBNP via renal filtration) create distinct analytical profiles:

•BNP reflects active neurohormonal signaling and is affected by neprilysin inhibition
•NT-proBNP provides a more stable, time-integrated measure of ventricular wall stress and is unaffected by neprilysin inhibition — a distinction that became critically important with the development of neprilysin inhibitor research (Myhre et al., 2019)

Biomarker Applications in Research

Natriuretic peptide biomarkers have transformed cardiovascular research methodology. Circulating BNP and NT-proBNP concentrations correlate with the degree of ventricular wall stress and neurohormonal activation, enabling researchers to:

•Stratify experimental cohorts by severity of cardiovascular dysfunction
•Monitor dynamic changes in cardiac hemodynamics across experimental protocols
•Evaluate the efficacy of novel cardiovascular interventions by tracking biomarker trajectories
•Study the relationship between cardiac natriuretic peptide secretion and extracardiac end-organ effects

A 2024 systematic review and meta-analysis confirmed the prognostic utility of both BNP and NT-proBNP as biomarkers in heart failure research, reinforcing their role as primary endpoints in cardiovascular investigation (Ammar et al., 2024).

---

Metabolic Research Applications

Natriuretic Peptides in Lipid Metabolism

A paradigm-expanding discovery revealed that natriuretic peptides activate lipolysis in human adipocytes through a cGMP/PKG-dependent pathway that is entirely independent of the canonical catecholamine/cAMP pathway (Sengenès et al., 2000). This finding opened a new research dimension:

•Lipolytic signaling: ANP binding to NPR-A on adipocytes stimulates cGMP production, activating PKG, which phosphorylates hormone-sensitive lipase (HSL) and perilipin, triggering triglyceride breakdown and free fatty acid mobilization. The potency order mirrors receptor affinity: ANP > BNP > CNP.

•Adipose browning: Natriuretic peptides promote the "browning" of white adipose tissue by inducing expression of uncoupling protein 1 (UCP1) and mitochondrial biogenesis genes through a p38 MAPK-dependent pathway downstream of cGMP/PKG signaling. This thermogenic activation represents a novel energy expenditure pathway (Moro et al., 2013).

•NPR-C as metabolic gatekeeper: Genetic and pharmacological studies have shown that reducing NPR-C expression or blocking its clearance function in adipose tissue enhances natriuretic peptide availability, potentiating lipolytic and thermogenic signaling. NPR-C expression is increased in obesity, potentially creating a state of natriuretic peptide deficiency that contributes to metabolic dysfunction.

Glucose Metabolism

Emerging research has linked natriuretic peptide signaling to glucose homeostasis. ANP enhances muscle glucose uptake independently of insulin through mechanisms involving AMPK activation and GLUT4 translocation. These metabolic actions position the natriuretic peptide system at the intersection of cardiovascular and metabolic research.

---

Skeletal Research Applications: CNP and Bone Growth

CNP as a Master Regulator of Endochondral Ossification

C-type natriuretic peptide has emerged as a critical regulator of linear bone growth. Through NPR-B activation in growth plate chondrocytes, CNP stimulates endochondral ossification by:

•Promoting chondrocyte proliferation and hypertrophy in the growth plate
•Activating cGMP/PKG-II signaling, which inhibits the MAPK/ERK pathway downstream of FGFR3
•Stimulating extracellular matrix production and cartilage differentiation

The biological importance of CNP/NPR-B in skeletal growth is underscored by both loss-of-function and gain-of-function genetic evidence. NPR-B loss-of-function mutations cause severe short stature (acromesomelic dysplasia type Maroteaux), while gain-of-function mutations in NPR2 result in a skeletal overgrowth phenotype (Nakao et al., 2010).

CNP Analogs in Skeletal Research

Vosoritide, a 39-amino-acid modified recombinant human CNP analog engineered for resistance to neprilysin degradation, has become a landmark molecule in translational skeletal research. By extending the half-life of CNP activity at NPR-B, vosoritide demonstrates that sustained CNP/NPR-B/cGMP signaling can promote linear bone growth in achondroplasia research models, where gain-of-function FGFR3 mutations constitutively activate the MAPK/ERK pathway that suppresses chondrocyte proliferation (Savarirayan et al., 2021). NTproCNP, the amino-terminal fragment of the CNP prohormone, has emerged as a research biomarker for growth velocity and growth plate activity, analogous to the role of NT-proBNP in cardiac research (Espiner et al., 2022).

---

Neprilysin Inhibition and the Natriuretic Peptide System

Enzymatic Degradation

Neprilysin (NEP, neutral endopeptidase 24.11, also known as CD10) is a zinc metalloprotease that cleaves natriuretic peptides at the ring structure, inactivating them. ANP is the preferred substrate for neprilysin, followed by CNP and BNP. This enzymatic degradation pathway, together with NPR-C-mediated clearance, determines circulating natriuretic peptide concentrations.

Neprilysin Inhibition as a Research Strategy

The rationale for neprilysin inhibition rests on augmenting endogenous natriuretic peptide levels to enhance their cardioprotective, vasodilatory, natriuretic, and anti-remodeling effects. However, neprilysin also degrades other vasoactive substrates including bradykinin, adrenomedullin, angiotensin I, angiotensin II, and endothelin-1, making isolated neprilysin inhibition a blunt pharmacological tool.

Sacubitril, a prodrug neprilysin inhibitor, has been studied in combination with the angiotensin receptor blocker valsartan. The PARADIGM-HF research program demonstrated that dual neprilysin/RAAS inhibition produced favorable cardiovascular outcomes compared to RAAS inhibition alone, providing strong evidence that enhancing natriuretic peptide bioavailability represents a viable research strategy for cardiovascular investigation (Myhre et al., 2019).

An important analytical consideration emerged from neprilysin inhibition research: because neprilysin degrades BNP but not NT-proBNP, circulating BNP levels increase during neprilysin inhibition while NT-proBNP levels decline — creating potential confusion in biomarker interpretation. This finding has led researchers to prefer NT-proBNP as the monitoring biomarker in the context of neprilysin inhibition studies.

---

Natriuretic Peptide-Based Therapeutic Research

Recombinant Peptide Analogs

Several recombinant and synthetic natriuretic peptide analogs are under active laboratory investigation:

•Carperitide (recombinant human ANP): Studied in cardiovascular research models for its vasodilatory, natriuretic, and anti-hypertrophic effects. Carperitide administration has demonstrated recovery of blood flow in ischemic conditions and exerted anti-fibrotic effects in preclinical models.

•Nesiritide (recombinant human BNP): Investigated for its natriuretic and vasodilatory actions in heart failure research settings.

•Cenderitide (CD-NP): A chimeric designer peptide that combines structural elements of CNP with the C-terminal tail of Dendroaspis natriuretic peptide (DNP, a natriuretic peptide from green mamba venom). Cenderitide activates both NPR-A and NPR-B, producing combined cardiovascular and skeletal effects with resistance to NPR-C-mediated clearance.

•MANP (mutant ANP): An engineered ANP variant with enhanced resistance to neprilysin degradation while retaining full NPR-A agonist activity, designed to overcome the rapid degradation that limits native ANP's utility in research.

Designer Peptides and the Future

The natriuretic peptide field is moving toward rationally designed peptide analogs that overcome the pharmacokinetic limitations of native peptides. Strategies include neprilysin-resistant mutations, NPR-C evasion through selective receptor targeting, PEGylation for half-life extension, and chimeric designs that combine desirable properties from multiple natriuretic peptide family members (Lee and Burnett, 2007).

---

Connections to Other Research Peptides

Counter-Regulatory Interactions

The natriuretic peptide system does not operate in isolation. Several peptides covered elsewhere on this platform interact directly with natriuretic peptide signaling:

•CGRP (Calcitonin Gene-Related Peptide): Like ANP, CGRP is a potent vasodilator. Both peptides reduce vascular resistance through distinct signaling pathways (cGMP for ANP vs. cAMP for CGRP), and their combined effects on cardiovascular hemodynamics are an active area of research.

•Apelin: The apelinergic system exerts cardiovascular effects that partially overlap with natriuretic peptides, including vasodilation and positive inotropy. Apelin and ANP appear to be co-regulated in the setting of cardiac volume overload.

•GLP-1 Agonists: GLP-1 receptor agonists including semaglutide and tirzepatide have demonstrated cardiovascular benefits that may involve crosstalk with the natriuretic peptide system. ANP promotes lipolysis through a pathway parallel to the metabolic effects of GLP-1 signaling, and the intersection of incretin and natriuretic peptide biology is a growing research frontier.

•Ghrelin: The ghrelin/GHS-R1a axis interacts with natriuretic peptide signaling in the regulation of energy homeostasis and cardiovascular function. Both systems modulate growth hormone secretion and have opposing effects on appetite regulation.

---

Analytical Considerations for Researchers

Peptide Handling and Stability

Natriuretic peptides present specific analytical challenges:

•Short half-lives: ANP (2–3 min) and BNP (20 min) are rapidly degraded by neprilysin and cleared by NPR-C. Researchers must account for rapid degradation when designing sample collection and processing protocols.

•Pre-analytical variables: EDTA plasma is preferred for BNP/NT-proBNP measurement. Sample hemolysis, lipemia, and delays in centrifugation can affect measured concentrations. Aprotinin (a protease inhibitor) should be added to blood collection tubes for ANP and BNP measurement to prevent in vitro degradation.

•Assay specificity: Multiple commercial immunoassays are available for BNP and NT-proBNP, but they measure different molecular forms and epitopes. Cross-reactivity between proBNP, BNP, and degradation fragments varies between assay platforms, complicating inter-laboratory comparison.

•Storage: Reconstituted natriuretic peptides should be aliquoted and stored at -80°C. Repeated freeze-thaw cycles significantly reduce peptide recovery. Lyophilized peptides should be stored desiccated at -20°C.

Structure-Activity Relationships

The disulfide-linked ring structure is absolutely required for natriuretic peptide receptor activation. Reduction of the disulfide bond abolishes biological activity. The N-terminal and C-terminal extensions modulate receptor selectivity and binding affinity:

•Removal of the C-terminal tail of ANP reduces NPR-A affinity
•The C-terminal tail of BNP contributes to its lower NPR-C affinity relative to ANP, partially explaining BNP's longer half-life
•CNP's lack of a C-terminal tail beyond the ring structure accounts for its NPR-B selectivity

---

Summary

The natriuretic peptide system — comprising ANP, BNP, and CNP with their receptors NPR-A, NPR-B, and NPR-C — represents a fundamental counter-regulatory axis in cardiovascular, renal, metabolic, and skeletal biology. From de Bold's paradigm-shifting 1981 discovery of the heart as an endocrine organ to the development of designer peptide analogs and neprilysin inhibition strategies, natriuretic peptide research continues to yield insights with broad implications.

For laboratory investigators, the natriuretic peptide system offers a rich landscape of research questions spanning receptor pharmacology, cGMP signaling, biomarker development, peptide engineering, and cross-system interactions with other bioactive peptide families. The system's involvement in cardiovascular homeostasis, lipid metabolism, adipose tissue biology, and skeletal growth ensures its continued centrality in peptide research.

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

References

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89-94. PubMed

2. Potter LR, Abbey-Hosch S, Bhatt DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;(191):341-366. PubMed

3. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69(2):318-328. PubMed

4. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35(7):419-425. PubMed

5. Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors. Peptides. 2005;26(6):1001-1008. PubMed

6. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26(6):1044-1059. PubMed

7. Pandey KN. The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms. FEBS J. 2011;278(11):1792-1807. PubMed

8. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14(10):1345-1351. PubMed

9. Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol. 2013;304(3):H358-368. PubMed

10. Nakao K, Kuwahara K, Nishikimi T, et al. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocr J. 2010;57(8):659-666. PubMed

11. Hanna T. Vosoritide: First Approval. Drugs. 2021;81(17):2057-2062. PubMed

12. Espiner EA, Prickett TCR. C-type natriuretic peptide and its contribution to bone growth. Osteologie. 2022;29(2):252-257. PubMed

13. Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019;73(11):1264-1272. PubMed

14. Ammar LA, et al. BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis. Heart Fail Rev. 2025;30(1). PubMed

15. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12(2):131-142. PubMed

---

Further Reading:

---

Disclaimer: This article is intended for educational and research purposes only. All compounds discussed are for Research Use Only (RUO) and are not intended for use in laboratory animals or in any products for human consumption. Always consult institutional guidelines and applicable regulations before conducting research with bioactive peptides.